Ocugen Inc (OCGN)

[vieuxcarre]

Will not. And you are going down

[harry crumb]

Stop, you know the deal, going nowhere

[vieuxcarre]

You’re a fool

[harry crumb]

So with all this so called excitement, theres no partner, there’s no funding, there’s no individual investors, there is no new news other than they will be out of cash by the end of the year or sooner, hhhmmmm, looks like inhaled company dilution about to happen any day now, sad and scary for anything positive here imo

[harry crumb]

$$$$$ again today

[harry crumb]

B under 1$ soon enough lol, no news on a partner, no news at all on anything, the perfect short folks $$$$$

[vieuxcarre]

STFU CLUELESS

[harry crumb]

If they announce an offering then there’s no partner, just saying. They are running out of money, about a year left.

[vieuxcarre]

Bahhahahaha

[harry crumb]

Shut up u asshole, get lost u POS, i never once used profanity on yur posts, yur a loser and go back in yur closet and hide scumbag

[vieuxcarre]

You’re a full blown jackass

[harry crumb]

Yeah i hear ya, ok best of luck

[TheUrbanFarmer]

We will see soon enough. FYI that’s what risk adjusted NPV’s are for, it’s how you can find the value of a drug in various stages of development. What you think companies like Novartis just spends $800m upfront with $700m more contingent on milestones for a phase 1 drug(GT005) to treat AMD based on random numbers lol?
Oh man, good luck harry. 🍻

[harry crumb]

It is still a speculative play imo, we long an short stocks, it’s how you make money on the same stock every day, indeed they may be onto something huge, if of course the fda is on their side with their models, yes the pps could go way higher on a financing deal or a partner but in these early stages of a trial its very doubtful, there is only a handful of patients dosed at this time. For big pharma to commit to millions of dollars i would believe they want to be 100% sure of what they are getting into. Time will tell an GL to you either way you play it. And by the way, they are burning through their cash pretty quick.

[TheUrbanFarmer]

There’s the problem about pulling numbers from a chart graph reflecting a pre rev bio during their R&D cash bleed stage.
Because what happens when the R&D stage yields great results and the company decides to bank off these results from selling regional rights, their cash runway all of a sudden overlaps their revenue timeline…
They then transform from a speculative bet to a bio poised to bring in billions of revenue yearly and the SP starts to reflect the pipeline’s fair value.
Here’s why $2.5 is laughable and only someone judging off the chart would predict that.
The risk adjusted Net Present Value of Ocu400 for just US/EU calculated with the most conservative numbers is worth 24x that market cap..
If the MENA region is even a fraction of the value of the US/EU market then this deal alone should be well over that $625m valuation.
Best part about all of it, is that this is just a fraction of Ocugens pipeline lmao.
Love you shorts, you have and will continue to make me a killing. 🍻

[harry crumb]

I doubt it, but then again ya just never know, imo this may reach the 2.25-2.50 area until further positive news arrives if any.

[TheUrbanFarmer]

A big pharma partnership you fool. Who shorts a company they don’t even know anything about? Determining the value of a pre rev bio based on their chart instead of their products is asking to get burned when they decide to sell some of those rights away.
Ocu400 licensing deal for the MENA region coming up. Imo with Novartis, deja vu 😉

[vieuxcarre]

Major shorts blown up

[gail]

i dont have a scanner but i find these on barcharts.com

they have all kinds of live lists,, not sure thats a scanner but its free. then i look at how they did in the past, and make a decision on how volume and upward movement looks, then i hop in.

[layton]

what scanner do you use to find these?

[harry crumb]

Around 2.40 area is the 3 yr resistance, its blown through everything else, an this is all on basically no major recent internally, news other than patient dosing, fda alignment and presentations, question is what is coming next, if anything….

[gail]

i see you just …..

…

got on here today but i assume you were in before, just not posted? anyway, lets do this!

[Triple nickle]

Friends weeeeeeee

[gail]

just smashed through 2 bucks!! weee!!

[Triple nickle]

Get ready 1.95

[gail]

about bust through 2 bucks!

[gail]

up 14% so far today

[vieuxcarre]

Ok fraud. What do you pretend to know that no one else does.

[glenn1919]

OCGN......................................https://stockcharts.com/h-sc/ui?s=OCGN&p=W&b=5&g=0&id=p86431144783

[harry crumb]

Lol, if you only knew….GL to you

[vieuxcarre]

Giddy up Harry Crumble

[harry crumb]

Unreal!

[gail]

busting 1.7 now, wow.

[gail]

busted past 1.60, just keeps going.

[gail]

here we goo! about to break 1.50 a/h!

[gail]

this is a VERY quiet board for a ….

..

stock that is going up. nice move up after hours here too! looks like a nice blast off is coming tomorrow.

[gail]

Grabbed some on the …

….

dip, ran like hell fall of 2021. trending up now, lets goooo!

[sgunderbarth]

Gm ocuhub. HOLDING

OCGN

[vieuxcarre]

Are you new.

[Monksdream]

OCGN under $2

[sgunderbarth]

1.06 going

OCGN

[Tradrdug17]

Lol you said they had no FDA status. But they do. And you never answered my question. Do you own shares of ocugen?

[Tradrdug17]

Lol crumb cake tastes a lot better than a MAGAt

[vieuxcarre]

Ok crumpet head

[vieuxcarre]

Trump is the only choice. Keep voting democratic crumb cake

[vieuxcarre]

Move on

[sgunderbarth]

Good afternoon, ocuhub

OCGN

[harry crumb]

Means nothing! All companies submitting phase trials must be in alignment with fda standards. You obviously know nothing about how protocols work and either does ocgn management. This ceo ran a previous company into bankruptcy lmao

[Tradrdug17]

https://www.stocktitan.net/news/OCGN/ocugen-gains-fda-alignment-on-key-aspects-of-ocu400-modifier-gene-z4kbny74xsft.html

[Tradrdug17]

It is spelled “and”. You must have went to trump university.